AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22990758 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing once a day (6 breaths/minute for 15 minutes)
Number of subjects: 92
Study 22990758 — intervention group
Group type: COMPARATOR
Intervention: Usual breathing (14 breaths/minute for 10 minutes/day)
Number of subjects: 92
Study 21071943 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver intervention
Number of subjects: 158
Study 21071943 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 158
Study 18656295 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Bond (GC)
Number of subjects: 52
Study 18656295 — intervention group
Group type: COMPARATOR
Intervention: Optibond FL (Kerr)
Number of subjects: 52
Study 16647408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixing insulin glargine (IG) with a rapid‐acting insulin (RAI) analogue
Number of subjects: 110
Study 16647408 — intervention group
Group type: COMPARATOR
Intervention: Control group (not mixing insulins)
Number of subjects: 110
Study 14662257 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of digoxin and carvedilol
Number of subjects: 47
Study 14662257 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 47
Study 14662257 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol alone
Number of subjects: 47
Study 14662257 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy to carvedilol alone
Number of subjects: 47
Study 14662257 — intervention group
Group type: COMPARATOR
Intervention: Any therapy
Number of subjects: 47
Study 11036893 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative-care intervention
Number of subjects: 434
Study 11036893 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control)
Number of subjects: 434
Study 8806342 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg sublingual nitrate tablet
Number of subjects: 100
Study 8806342 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg sublingual nitrate spray
Number of subjects: 100
Study 8806342 — intervention group
Group type: EXPERIMENTAL
Intervention: water + 0.3 mg sublingual nitrate tablet
Number of subjects: 100
Study 8806342 — intervention group
Group type: EXPERIMENTAL
Intervention: water + 0.4 mg sublingual nitrate spray
Number of subjects: 100
Study 8806342 — intervention group
Group type: COMPARATOR
Intervention: control (no nitrate)
Number of subjects: 100
Study 12319159 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-session sex education program delivered by teachers
Number of subjects: 586
Study 6199185 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic children
Number of subjects: 23
Study 6199185 — intervention group
Group type: COMPARATOR
Intervention: Normal children
Number of subjects: 23
Study 31056784 — intervention group
Group type: EXPERIMENTAL
Intervention: Online group MBCR during chemotherapy
Number of subjects: 178
Study 31056784 — intervention group
Group type: COMPARATOR
Intervention: Waitlist usual care (control)
Number of subjects: 178
Study 29961059 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride (40 mmol/day)
Number of subjects: 399
Study 29961059 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (40 mmol/day)
Number of subjects: 399
Study 29961059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 29961059 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 399
Study 27084721 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir 25/150/100 mg once a day for 12 weeks
Number of subjects: 363
Study 27084721 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Number of subjects: 363
Study 24725797 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release (MFR)
Number of subjects: 80
Study 24725797 — intervention group
Group type: COMPARATOR
Intervention: Sham Myofascial release (SMFR)
Number of subjects: 80
Study 22914302 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physiotherapy and acupuncture
Number of subjects: 56
Study 22914302 — intervention group
Group type: COMPARATOR
Intervention: Standardised exercise and advice leaflet (Control)
Number of subjects: 56
Study 19962240 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment
Number of subjects: 14
Study 16988198 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg E2 and 22.5 mg/kg P per day (E2/P)
Number of subjects: 29
Study 16988198 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 29
Study 16988198 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/P
Number of subjects: 29
Study 16988198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15481552 — intervention group
Group type: EXPERIMENTAL
Intervention: Training course (Group A and Group C)
Number of subjects: 3
Study 15481552 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of education (for workers)
Number of subjects: 3
Study 15481552 — intervention group
Group type: COMPARATOR
Intervention: No training course (Group B)
Number of subjects: 3
Study 10775867 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid 1% ointment
Number of subjects: 7
Study 10775867 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 7
Study 9357096 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous morphine drips (10‐40 micrograms/kg.h) in pediatric patients
Number of subjects: 15
Study 9357096 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen with 8 mg codeine (n = 13) or 30 mg codeine (n = 5) in adult volunteers
Number of subjects: 15
Study 7691019 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight dextran (MW = 40,000)
Number of subjects: 21
Study 7691019 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment period (20 days)
Number of subjects: 21
Study 3779500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg + saline
Number of subjects: 60
Study 3779500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg + metoclopramide 10 mg
Number of subjects: 60
Study 3779500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg + saline
Number of subjects: 60
Study 3779500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg + metoclopramide 10 mg
Number of subjects: 60
Study 31720889 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG-guided blood product transfusion
Number of subjects: 58
Study 31720889 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 58
Study 29792372 — intervention group
Group type: EXPERIMENTAL
Intervention: THC:CBD oromucosal spray (Sativex®)
Number of subjects: 191
Study 29792372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 28263227 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized physical therapy (10 sessions targeting pathoanatomical, psychosocial, and neurophysiological factors)
Number of subjects: 300
Study 28263227 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based advice (2 sessions)
Number of subjects: 300
Study 25901479 — intervention group
Group type: EXPERIMENTAL
Intervention: FPNS 1 × 100 μg
Number of subjects: 13
Study 25901479 — intervention group
Group type: EXPERIMENTAL
Intervention: FPNS 2 × 100 μg at 4-hour intervals
Number of subjects: 13
Study 25901479 — intervention group
Group type: EXPERIMENTAL
Intervention: FPNS 8 × 100 μg consecutively
Number of subjects: 13
Study 25901479 — intervention group
Group type: EXPERIMENTAL
Intervention: FPNS (all regimens)
Number of subjects: 13
Study 23719682 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone bitartrate ER capsules
Number of subjects: 220
Study 21818869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixim
Number of subjects: 0
Study 21818869 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 0
Study 17420366 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ETDRS laser photocoagulation
Number of subjects: 263
Study 17420366 — intervention group
Group type: COMPARATOR
Intervention: Mild macular grid (MMG) laser technique
Number of subjects: 263
Study 15821964 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 3He MRI
Number of subjects: 35
Study 15821964 — intervention group
Group type: COMPARATOR
Intervention: 81mKr SPECT
Number of subjects: 35
Study 11916791 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2.5 microg/kg
Number of subjects: 107
Study 11916791 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5.0 microg/kg
Number of subjects: 107
Study 11916791 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 107
Study 9876334 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (3x5 mg/day p.o.)
Number of subjects: 10
Study 9876334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (2x1 mg/day p.o. for three weeks)
Number of subjects: 10
Study 9876334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8578757 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis with specific suggestions for elimination of pain
Number of subjects: 22
Study 2244710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized atropine methylnitrate (AMN) + albuterol (ALB)
Number of subjects: 8
Study 2244710 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (ALB)
Number of subjects: 8
Study 748436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheltered Workshops
Number of subjects: 30
Study 748436 — intervention group
Group type: EXPERIMENTAL
Intervention: Reality Orientation
Number of subjects: 30
Study 748436 — intervention group
Group type: COMPARATOR
Intervention: Assessment‐only control
Number of subjects: 30
Study 31129917 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy care (medication review, regular dose dispensing, and counselling)
Number of subjects: 237
Study 31129917 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 237
Study 28818994 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein 100 mg/day
Number of subjects: 84
Study 28818994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 25938990 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) with vitamins and 5000 IU of dalteparin-sodium for up to 24 weeks' gestation
Number of subjects: 449
Study 25938990 — intervention group
Group type: COMPARATOR
Intervention: Control group received multivitamin pills
Number of subjects: 449
Study 25938990 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 449
Study 24121976 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg per day for 6 months (Group 1)
Number of subjects: 46
Study 24121976 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 2)
Number of subjects: 46
Study 21508756 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-literacy Medicaid‐Title XIX Sterilization Consent Form (n=102)
Number of subjects: 201
Study 21508756 — intervention group
Group type: COMPARATOR
Intervention: Standard Medicaid‐Title XIX Sterilization Consent Form (n=99)
Number of subjects: 201
Study 19464613 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 microg/kg for 10 min, followed by 0.7 microg x kg(‐1) x hr(‐1) continuous infusion)
Number of subjects: 30
Study 19464613 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ESC of fentanyl = 2 ng/mL)
Number of subjects: 30
Study 19464613 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ESC of fentanyl = 4 ng/mL)
Number of subjects: 30
Study 16681478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25, 50, 100 mg, as needed)
Number of subjects: 300
Study 16681478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 14872172 — intervention group
Group type: EXPERIMENTAL
Intervention: PncDT11 vaccine
Number of subjects: 252
Study 11566639 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg PEG-OB protein/wk for 12 weeks
Number of subjects: 30
Study 11566639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9692687 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m.
Number of subjects: 169
Study 9692687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 8154486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein intake of 1.3 g/kg body weight/d
Number of subjects: 61
Study 8154486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein intake of 0.575 g/kg body weight/d
Number of subjects: 61
Study 8154486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein intake of 0.28 g/kg body weight/d (supplemented with amino acids or their keto analogs)
Number of subjects: 61
Study 8154486 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diets
Number of subjects: 61
Study 8154486 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline to follow-up change in protein intake
Number of subjects: 61
Study 8154486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of fats
Number of subjects: 61
Study 8154486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of cholesterol
Number of subjects: 61
Study 2645846 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression stockings alone (group 1)
Number of subjects: 239
Study 2645846 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression stockings plus intermittent pneumatic compression (IPC) (group 2)
Number of subjects: 239
Study 2645846 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 239
Study 1137255 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of prednisone every 8 hours (Group A)
Number of subjects: 60
Study 1137255 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg of prednisone every morning (Group B)
Number of subjects: 60
Study 1137255 — intervention group
Group type: COMPARATOR
Intervention: 90 mg of prednisone every other morning (Group C)
Number of subjects: 60
Study 1137255 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions to prednisone (Groups A and B)
Number of subjects: 60
Study 31184941 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Controlled Local Anesthetic Delivery System (CCLADS)
Number of subjects: 82
Study 31184941 — intervention group
Group type: COMPARATOR
Intervention: Conventional intraligamentary injection
Number of subjects: 82
Study 28200017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored preventive oral health intervention
Number of subjects: 269
Study 28200017 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 269
Study 26317978 — intervention group
Group type: EXPERIMENTAL
Intervention: COBAS Amplicor V2, Roche (CA) (lower detection limit 50 IU/ml)
Number of subjects: 429
Study 26317978 — intervention group
Group type: EXPERIMENTAL
Intervention: VERSANT HCV-RNA Qualitative Assay, Siemens (TMA) (lower limit detection 10 IU/ml)
Number of subjects: 429
Study 26317978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CA and TMA undetectable
Number of subjects: 429
Study 26317978 — intervention group
Group type: EXPERIMENTAL
Intervention: CA undetectable/TMA positive
Number of subjects: 429
Study 26317978 — intervention group
Group type: EXPERIMENTAL
Intervention: TMA undetectable patients (14 weeks treatment)
Number of subjects: 429
Study 26317978 — intervention group
Group type: EXPERIMENTAL
Intervention: TMA positive patients (14 weeks treatment)
Number of subjects: 429
Study 26317978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CA and TMA undetectable (genotype 2, 14 weeks treatment)
Number of subjects: 429
Study 22632925 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone motivational interviewing (MI)
Number of subjects: 73
Study 22632925 — intervention group
Group type: COMPARATOR
Intervention: Standard referral and four neutral telephone check-in sessions (control)
Number of subjects: 73
Study 20187348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine hydrochloride (Zyrtec, 10 mg)
Number of subjects: 83
Study 20187348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 18583464 — intervention group
Group type: COMPARATOR
Intervention: Diet only (DO)
Number of subjects: 94
Study 18583464 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and aerobic exercise (DA)
Number of subjects: 94
Study 18583464 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and combined aerobic-resistance exercise (DC)
Number of subjects: 94
Study 18583464 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (DO, DA, DC)
Number of subjects: 94
Study 16029782 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridium 192 boost technique
Number of subjects: 142
Study 16029782 — intervention group
Group type: COMPARATOR
Intervention: Photon/electron boost technique
Number of subjects: 142
Study 11802244 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX (8‐cyclopentyl‐1,3‐dipropylxanthine) at doses of 1, 3, 10, 30, 100, 300, and 1,000 mg
Number of subjects: 37
Study 11802244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 11802244 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX (8‐cyclopentyl‐1,3‐dipropylxanthine)
Number of subjects: 37
Study 10051781 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based intervention program emphasizing nursing involvement, physician education, provider prompts, audiovisual and printed patient education materials, transportation assistance (bus passes), preappointment reminders, and rescheduling assistance
Number of subjects: 314
Study 10051781 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 314
Study 7747622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative intake of aluminum gels
Number of subjects: 256
Study 7747622 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis with supraphysiologic calcium concentrations
Number of subjects: 256
Study 7747622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of calcium carbonate
Number of subjects: 256
Study 7747622 — intervention group
Group type: EXPERIMENTAL
Intervention: History of diabetes mellitus
Number of subjects: 256
Study 2245928 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 0
Study 2245928 — intervention group
Group type: COMPARATOR
Intervention: ASA (Aspirin)
Number of subjects: 0
Study 6455734 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (conditioning exercises twice a week for eight weeks)
Number of subjects: 0
Study 6455734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic counselling
Number of subjects: 0
Study 6455734 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30205697 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback with blinded peer comparison
Number of subjects: 6
Study 30205697 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 6
Study 28992192 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Pressure Variability Ratio (BPVR)
Number of subjects: 772
Study 28992192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Wave Velocity (PWV)
Number of subjects: 772
Study 28992192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory Arterial Stiffness Index (AASI)
Number of subjects: 772
Study 26489804 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg and Ezetimibe 10 mg daily
Number of subjects: 1656
Study 26489804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1656
Study 23128915 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal (TF) epidural steroid injection (ESI)
Number of subjects: 0
Study 23128915 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlaminar (IL) epidural steroid injection (ESI)
Number of subjects: 0
Study 21845341 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST, N = 13, twice a week, 70‐90% 1‐RM)
Number of subjects: 39
Study 21845341 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Training (PT, N = 15, twice a week, 30‐50% 1‐RM)
Number of subjects: 39
Study 21845341 — intervention group
Group type: COMPARATOR
Intervention: Control (N = 11)
Number of subjects: 39
Study 21845341 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data for all groups
Number of subjects: 39
Study 19303810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity continuous Theta Burst Stimulation (cTBS)
Number of subjects: 9
Study 19303810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity intermittent Theta Burst Stimulation (iTBS)
Number of subjects: 9
Study 17470434 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 535
Study 17470434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study 16249836 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 MP consumer color display
Number of subjects: 9
Study 16249836 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 MP business color display
Number of subjects: 9
Study 16249836 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 MP medical-grade gray display
Number of subjects: 9
Study 16249836 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MP gray display
Number of subjects: 9
Study 16249836 — intervention group
Group type: EXPERIMENTAL
Intervention: All displays
Number of subjects: 9
Study 16249836 — intervention group
Group type: EXPERIMENTAL
Intervention: All users
Number of subjects: 9
Study 12930498 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Overdrive (MO) pacing at 10-19 beats/min > mean heart rate
Number of subjects: 42
Study 12930498 — intervention group
Group type: EXPERIMENTAL
Intervention: High Overdrive (HO) pacing at 20-29 beats/min > mean heart rate
Number of subjects: 42
Study 12930498 — intervention group
Group type: COMPARATOR
Intervention: No pacing (OAO mode)
Number of subjects: 42
Study 12930498 — intervention group
Group type: EXPERIMENTAL
Intervention: No difference between MO and HO pacing
Number of subjects: 42
Study 10823594 — intervention group
Group type: EXPERIMENTAL
Intervention: Abduction splintage
Number of subjects: 44
Study 10823594 — intervention group
Group type: COMPARATOR
Intervention: Observation (unsplinted group)
Number of subjects: 44
Study 10823594 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 44